Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
LUCE, BRYAN R.
DRUMMOND, MICHAEL
JÖNSSON, BENGT
NEUMANN, PETER J.
SCHWARTZ, J. SANFORD
SIEBERT, UWE
and
SULLIVAN, SEAN D.
2010.
EBM, HTA, and CER: Clearing the Confusion.
Milbank Quarterly,
Vol. 88,
Issue. 2,
p.
256.
Signorovitch, James E.
Wu, Eric Q.
Yu, Andrew P.
Gerrits, Charles M.
Kantor, Evan
Bao, Yanjun
Gupta, Shiraz R.
and
Mulani, Parvez M.
2010.
Comparative Effectiveness Without Head-to-Head Trials.
PharmacoEconomics,
Vol. 28,
Issue. 10,
p.
935.
Gibson, J. Mark
and
Little, Alison
2010.
HTA principles need rigorous review.
International Journal of Technology Assessment in Health Care,
Vol. 26,
Issue. 4,
p.
428.
Backhouse, Martin E.
Wonder, Michael
Hornby, Edward
Kilburg, Anne
Drummond, Michael
and
Mayer, Friedrich Karl
2011.
Early Dialogue Between the Developers of New Technologies and Pricing and Reimbursement Agencies: A Pilot Study.
Value in Health,
Vol. 14,
Issue. 4,
p.
608.
Kolasa, Katarzyna
Dziomdziora, Malgorzata
and
Fajutrao, Liberty
2011.
What aspects of the health technology assessment process recommended by international health technology assessment agencies received the most attention in Poland in 2008?.
International Journal of Technology Assessment in Health Care,
Vol. 27,
Issue. 1,
p.
84.
Grutters, Janneke P.C.
Seferina, Shanly C.
Tjan-Heijnen, Vivianne C.G.
van Kampen, Roel J.W.
Goettsch, Wim G.
and
Joore, Manuela A.
2011.
Bridging Trial and Decision: A Checklist to Frame Health Technology Assessments for Resource Allocation Decisions.
Value in Health,
Vol. 14,
Issue. 5,
p.
777.
Mauskopf, Josephine
Walter, Jeffrey
Birt, Julie
Bowman, Lee
Copley-Merriman, Catherine
and
Drummond, Michael
2011.
Differences among formulary submission guidelines: Implications for health technology assessment.
International Journal of Technology Assessment in Health Care,
Vol. 27,
Issue. 3,
p.
261.
Fischer, Katharina E.
Grosse, Scott D.
and
Rogowski, Wolf H.
2011.
The role of health technology assessment in coverage decisions on newborn screening.
International Journal of Technology Assessment in Health Care,
Vol. 27,
Issue. 4,
p.
313.
Mitchell, Matthew D.
Williams, Kendal
Kuntz, Gretchen
and
Umscheid, Craig A.
2011.
When the decision is what to decide: Using evidence inventory reports to focus health technology assessments.
International Journal of Technology Assessment in Health Care,
Vol. 27,
Issue. 2,
p.
127.
Ciani, Oriana
Tarricone, Rosanna
and
Torbica, Aleksandra
2012.
Diffusion and use of health technology assessment in policy making: What lessons for decentralised healthcare systems?.
Health Policy,
Vol. 108,
Issue. 2-3,
p.
194.
Picavet, E.
Annemans, L.
Cleemput, I.
Cassiman, D.
and
Simoens, S.
2012.
Market uptake of orphan drugs - a European analysis.
Journal of Clinical Pharmacy and Therapeutics,
Vol. 37,
Issue. 6,
p.
664.
Burch, Jane
Griffin, Susan
McKenna, Claire
Walker, Simon
Paton, James
Wright, Kath
and
Woolacott, Nerys
2012.
Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6–11 Years.
PharmacoEconomics,
Vol. 30,
Issue. 11,
p.
991.
Neumann, Peter J.
Bliss, Sarah K.
and
Chambers, James D.
2012.
Therapies For Advanced CancersPose A Special Challenge For Health Technology Assessment Organizations In Many Countries.
Health Affairs,
Vol. 31,
Issue. 4,
p.
700.
Persson, Ulf
Svensson, Johanna
and
Pettersson, Billie
2012.
A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing.
Applied Health Economics and Health Policy,
Vol. 10,
Issue. 4,
p.
217.
Drummond, Michael
Neumann, Peter
Jönsson, Bengt
Luce, Bryan
Schwartz, J. Sanford
Siebert, Uwe
and
Sullivan, Sean D.
2012.
CAN WE RELIABLY BENCHMARK HEALTH TECHNOLOGY ASSESSMENT ORGANIZATIONS?.
International Journal of Technology Assessment in Health Care,
Vol. 28,
Issue. 2,
p.
159.
Signorovitch, James
Erder, M. Haim
Xie, Jipan
Sikirica, Vanja
Lu, Mei
Hodgkins, Paul S.
and
Wu, Eric Q.
2012.
Comparative effectiveness research using matching‐adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention‐deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Pharmacoepidemiology and Drug Safety,
Vol. 21,
Issue. S2,
p.
130.
Quinn, Bruce
Giffin, Robert B.
and
Tunis, Sean R.
2013.
Genomic and Personalized Medicine.
p.
457.
Mathes, Tim
Jacobs, Esther
Morfeld, Jana-Carina
and
Pieper, Dawid
2013.
Methods of international health technology assessment agencies for economic evaluations- a comparative analysis.
BMC Health Services Research,
Vol. 13,
Issue. 1,
Sculpher, Mark
2013.
Methods Development for Health Technology Assessment.
Medical Decision Making,
Vol. 33,
Issue. 3,
p.
313.
Novaes, Hillegonda Maria Dutilh
and
Elias, Flávia Tavares Silva
2013.
Uso da avaliação de tecnologias em saúde em processos de análise para incorporação de tecnologias no Sistema Único de Saúde no Ministério da Saúde.
Cadernos de Saúde Pública,
Vol. 29,
Issue. suppl 1,
p.
s7.